Shattuck Labs (NASDAQ:STTK) announced plans to evaluate SL-325 in a Phase 2 clinical trial for patients with moderate to severe hidradenitis suppurativa (HS), expanding the program beyond its existing inflammatory bowel disease development.
Shattuck Labs (NASDAQ:STTK) reported a narrowed net loss for fiscal year 2025, driven by a strategic reduction in research and development expenses and a disciplined focus on its lead clinical programs.
Shattuck Labs (NASDAQ:STTK) reported a $15.2 million Q2 2026 net loss with no revenue while advancing lead candidate SL-325.
Shattuck Labs (NASDAQ:STTK) announced positive top-line results from its Phase 1 clinical trial of SL-325, a novel Death Receptor 3 (DR3) blocking antibody.
